038070 — Seoulin Bioscience Co Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapNeutral

Annual balance sheet for Seoulin Bioscience Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	18,860	73,282	52,794	32,878	22,358
Net Total Accounts Receivable
Net Total Receivables	8,908	10,333	9,578	15,509	9,591
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	41,462	100,846	87,287	72,955	59,841
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	14,541	14,937	16,491	18,914	16,628
Net Goodwill
Net Intangible Assets
Long Term Investments
Long Term Notes Receivable
Other Long Term Assets
Total Assets	78,247	136,566	135,486	114,100	101,525
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	13,533	24,808	46,365	28,030	13,634
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Minority Interest
Total Other Liabilities
Total Funded Status
Total Liabilities	18,327	61,705	51,083	31,037	17,632
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Treasury Stock
Unrealized Gain / Loss
Other Equity
Total Equity	59,920	74,861	84,403	83,063	83,893
Total Liabilities & Shareholders' Equity	78,247	136,566	135,486	114,100	101,525
Total Common Shares Outstanding